General insurers have said that they will settle claims on the health policies of individuals undergoing treatment for mucormycosis or black fungus, the incidence of which has increased as a result of COVID-19 infections.
If you are already a subscriber
OR sign-up for a trial access here
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
Brought to you by